"MKN-45人胃癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

傳代比例：1:2-1:4(首次傳代建議1:2)

生長特性：貼壁生長

細(xì)胞系的應(yīng)用：1)免疫組化研究2)RNA干擾研究3)藥物作用研究4)慢病毒轉(zhuǎn)染研究等其它應(yīng)用。細(xì)胞系通常用于實驗研究，如增殖、遷移、侵襲等。細(xì)胞系在多個領(lǐng)域的研究中被廣泛應(yīng)用，包括基礎(chǔ)醫(yī)學(xué)、臨床試驗、藥物篩選和分子生物學(xué)研究。這些研究不僅在中國，也在日本、美國和歐洲等多個國家和地區(qū)進(jìn)行。

換液周期：每周2-3次

293E Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：１０傳代；每周２次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：INS-1E細(xì)胞、LS 174 T細(xì)胞、SHP77細(xì)胞

Panc 02.03 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HES [Human embryonic skin fibroblast]細(xì)胞、VK2/E6E7細(xì)胞、CCD-841CoN細(xì)胞

3T3J2 Cells;背景說明：胚胎；成纖維 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：UMRC2細(xì)胞、CAL-39細(xì)胞、HEK-293-FT細(xì)胞

MKN-45人胃癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

背景信息：該細(xì)胞系由S Akiyama建立，源于一位３５歲患有印戒細(xì)胞癌的女性的胃淋巴結(jié)。

┈訂┈購(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

貼壁細(xì)胞的傳代培養(yǎng)，詳細(xì)步驟如下：首先倒掉培養(yǎng)基，在這一步驟可以收集一些細(xì)胞上清做支原體檢測；加入胰蛋白酶，一般T25是加2mL，蓋好瓶蓋，搖晃T25培養(yǎng)瓶，使胰蛋白酶均勻覆蓋在細(xì)胞表面，放入培養(yǎng)箱2-3min，期間可在顯微鏡下觀察，看到大部分細(xì)胞變圓，即可放入超凈臺，加入2倍的完全培養(yǎng)基，這里就是加4mL培養(yǎng)基，終止消化；將含有胰蛋白酶，細(xì)胞和培養(yǎng)基一起轉(zhuǎn)移到離心管中，1000rpm/3min離心，去掉上清；新鮮的完全培養(yǎng)基重懸，根據(jù)細(xì)胞的生長特性和后續(xù)的實驗需求進(jìn)行傳代，比如我養(yǎng)的Hepa1-6就長的比較快，不是著急用的話，我就會按1E6個細(xì)胞/T75培養(yǎng)瓶進(jìn)行傳代；但如果后兩天要用，就會適當(dāng)多傳一點；還可通過顯微鏡計數(shù)后，直接用于細(xì)胞鋪板，繼續(xù)后續(xù)的實驗。

產(chǎn)品包裝：復(fù)蘇發(fā)貨：T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨：1ml凍存管(兩支)

來源說明：細(xì)胞主要來源ATCC、ECACC、DSMZ、RIKEN等細(xì)胞庫

MKN-45人胃癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

物種來源：人源、鼠源等其它物種來源

NCI-H740 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：LA-N-6細(xì)胞、AM細(xì)胞、Panc_08_13細(xì)胞

L-cell Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MC116細(xì)胞、TW-039細(xì)胞、NCI-H1755細(xì)胞

C4-I Cells;背景說明：宮頸鱗癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：BpRc1細(xì)胞、D-341 Med細(xì)胞、Hs 888.Lu細(xì)胞

CHL1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：６—１：１０傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：MBMEC細(xì)胞、NCI-H220細(xì)胞、MDA157細(xì)胞

┈訂┈購(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

形態(tài)特性：上皮細(xì)胞樣

細(xì)胞培養(yǎng)無菌操作步驟和注意事項：１.打開無菌工作臺及凈化室的紫外燈，消毒半小時以上。２.進(jìn)入凈化室前先關(guān)閉紫外燈，打開超凈臺風(fēng)機，等待３０min以上，以排盡臭氧。３.穿HAO隔離衣，戴HAO口罩，帽子。４.風(fēng)淋２分鐘。５.０.１%水泡手，擦干。６.點燃酒精燈;超凈臺內(nèi)應(yīng)避免放入過多的物品;使用的吸管，滴管，試管，培養(yǎng)瓶等均事先滅菌。７.打開各類瓶蓋前先過火，以固定灰塵;打開的瓶口、試管口過火焰，鑷子使用前應(yīng)經(jīng)火焰燒灼。８.水平式風(fēng)機的超凈臺，應(yīng)使瓶口斜置，應(yīng)盡量避免瓶口敞開直立。９.同一根吸管或滴管不應(yīng)連續(xù)用于幾個不同的細(xì)胞系；吸取培養(yǎng)基的吸管應(yīng)離開培養(yǎng)瓶或試管口０.５cm，避免伸入培養(yǎng)瓶口或試管口；以防止細(xì)胞系的互相混雜污染。１０.漏在培養(yǎng)瓶上或臺上的體，立即用酒精棉球擦凈。１１.操作完畢后恢復(fù)工作臺面。

CAL 51 Cells;背景說明：乳腺癌；胸腔積液轉(zhuǎn)移；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Bac 1.2F5細(xì)胞、Hs27細(xì)胞、L540細(xì)胞

TE12 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：UMNSAH/DF#1細(xì)胞、Rat podocyte細(xì)胞、OCI-Ly 1細(xì)胞

JeKo 1 Cells;背景說明：一位套細(xì)胞淋巴瘤患者的巨細(xì)胞變種顯示白血病轉(zhuǎn)變，從其外周血單核細(xì)胞出發(fā)建立了MCL細(xì)胞株JeKo-１。 JeKo-１細(xì)胞EB病毒陰性，并表達(dá)一種B細(xì)胞表型的IgM。 細(xì)胞過表達(dá)cyclin D１, Bcl-２, c-Myc 及 Rb 蛋白。 Bcl-１/J(H)基因重排得到了PCR證實。 JeKo-１細(xì)胞在SCID小鼠中高成瘤。 [PubMed: ９７５３０６３];傳代方法：１：２傳代。３天內(nèi)可長滿。;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：HPAF-2細(xì)胞、TE-8細(xì)胞、hOMF細(xì)胞

HEC-1A Cells;背景說明：這株細(xì)胞及其亞株HEC-１-B是H.Kuramoto及其同事１９６８年從一位IA期子宮內(nèi)膜癌患者身上分離得到的。PAF可以誘導(dǎo)其c-fos的表達(dá)。;傳代方法：消化３-５分鐘，１：２,３天內(nèi)可長滿;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Oka-C1細(xì)胞、SK Col 1細(xì)胞、OEC33細(xì)胞

HGC-27 Cells;背景說明：未分化胃癌，能分泌粘液素。;傳代方法：消化３-５分鐘，１：２,３天內(nèi)可長滿;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：FLS細(xì)胞、H510細(xì)胞、Roswell Park Memorial Institute 7951細(xì)胞

SACC-LM Cells;背景說明：涎腺腺樣囊性癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HIEC6細(xì)胞、HCC-1187細(xì)胞、Tu-177細(xì)胞

DiFi Cells;背景說明：結(jié)直腸癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SUDHL10細(xì)胞、MLM細(xì)胞、8305C細(xì)胞

TALL 1 Cells;背景說明：該細(xì)胞源于一名復(fù)發(fā)T-ALL（急性T淋巴細(xì)胞性白血?。┑膬和耐庵苎痪哂泻軓姷募?xì)胞毒性，體內(nèi)體外實驗中都能破壞腫瘤細(xì)胞；IL-２可使細(xì)胞更好地生長；α/β TCR陽性，γ/δ TCR陰性；可產(chǎn)生IFNγ、TNF-α和GM-CSF。;傳代方法：維持細(xì)胞密度在４×１０５-１×１０６ cells/ml之間，２-３天換液１次　;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：Michigan Cancer Foundation-12F細(xì)胞、SW837細(xì)胞、MPC-5細(xì)胞

EFM-19 Cells;背景說明：乳腺管癌；胸腔積液轉(zhuǎn)移；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SKMES細(xì)胞、RD-ES細(xì)胞、HT-115細(xì)胞

BEL/FU Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：KOSC-2 cl3-43細(xì)胞、HBL1細(xì)胞、RT-BM細(xì)胞

no-11 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：MiaPaca.2細(xì)胞、KMB-17細(xì)胞、HRIF細(xì)胞

S3 HeLa Cells;背景說明：該細(xì)胞是１９５５年由PuckTT,MarcusPI和CieciuraSJ建系的，含HPV-１８序列；角蛋白陽性；可用于與染色體突變、細(xì)胞營養(yǎng)、集落形成相關(guān)的哺乳動物細(xì)胞的克隆分析。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：MDA-MB 231細(xì)胞、MPVECs細(xì)胞、Melan-a細(xì)胞

GM04154B Cells;背景說明：急性T淋巴細(xì)胞白血??；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CG-4細(xì)胞、HCV-29細(xì)胞、SNU-354細(xì)胞

MC-3T3 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CESS細(xì)胞、A-172MG細(xì)胞、RFL 6細(xì)胞

CCD-841CoTr Cells;背景說明：結(jié)腸癌；SV４０轉(zhuǎn)化；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Fao細(xì)胞、NuTu 19細(xì)胞、UPCI-SCC-090細(xì)胞

HCC1171 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Wistar Institute-38細(xì)胞、MiaPaCa-2細(xì)胞、DSL-6A/C1細(xì)胞

HUVSMC Cells;背景說明：臍靜脈平滑肌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H1436細(xì)胞、H2081細(xì)胞、SKMEL-1細(xì)胞

1023SevF Cells(提供STR鑒定圖譜)

Abcam HEK293T YBX3 KO Cells(提供STR鑒定圖譜)

AG13443 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line RRD113 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XE861 Cells(提供STR鑒定圖譜)

BY00610 Cells(提供STR鑒定圖譜)

CT26.WT-mNIS (monoclonal) Cells(提供STR鑒定圖譜)

DA04594 Cells(提供STR鑒定圖譜)

foec-5 Cells(提供STR鑒定圖譜)

H1793 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：６傳代 ;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：TGW-nu-1細(xì)胞、SVEC 4-10細(xì)胞、SK Mel 1細(xì)胞

MKN-45人胃癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

NCI-H1355 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每周換液２次。;生長特性：懸浮生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCI-H1618細(xì)胞、COLO-1細(xì)胞、T 24細(xì)胞

BIC-1 Cells;背景說明：食管腺癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：BALB/c 3T3 clone A31細(xì)胞、SW-756細(xì)胞、ONS76細(xì)胞

RPMI7951 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代，２天換液１次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：SK-N-BE(2)-C細(xì)胞、HT144細(xì)胞、TGW-nu細(xì)胞

T-T Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１０^５ cells/６０mm dish;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：CWR22-Rv1細(xì)胞、32D clone3細(xì)胞、SBC-5細(xì)胞

GM03569D Cells;背景說明：該細(xì)胞是由綿羊紅細(xì)胞免疫的BALB/c小鼠脾細(xì)胞和P３X６３Ag８骨髓瘤細(xì)胞融合得到的。該細(xì)胞不分泌免疫球蛋白，對２０μg/ml的８-氮鳥嘌呤有抗性，對HAT比較敏感；該細(xì)胞可以作為細(xì)胞融合時的B細(xì)胞組分用于制備雜交瘤；鼠痘病毒陰性。;傳代方法：１：２傳代;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞樣；圓形;相關(guān)產(chǎn)品有：MSTO-211H細(xì)胞、MDA MB 175 VII細(xì)胞、HL-60 clone15細(xì)胞

1-903-430 Cells(提供STR鑒定圖譜)

HepG2/C3A Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３—１：６傳代，每周換液２次;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：SUM-102PT細(xì)胞、HUCCT1細(xì)胞、LS411細(xì)胞

LY Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H7721細(xì)胞、H35 Reuber細(xì)胞、Karpas-422細(xì)胞

SUDHL-2 Cells;背景說明：彌漫性大細(xì)胞淋巴瘤；胸腔積液轉(zhuǎn)移；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：LP-1細(xì)胞、SK-N-BE-2細(xì)胞、8226細(xì)胞

Hs-343-T Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２—１：３傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：FL83B細(xì)胞、RCK-8細(xì)胞、HCT FET細(xì)胞

HT144-mel Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：８傳代，２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：MDA MB 436細(xì)胞、C6細(xì)胞、IHH細(xì)胞

SKNO-1 Cells;背景說明：急性髓系白血??；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HEC-151細(xì)胞、IEC-18細(xì)胞、C32 [Human melanoma]細(xì)胞

PLC Cells;背景說明：該細(xì)胞系分泌乙肝病毒表面抗原（HBsAg）。 此細(xì)胞系原先被支原體污染，后用BM-cycline去除支原體;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Hs739T細(xì)胞、RPMI-1788細(xì)胞、OVCA-432細(xì)胞

SUDHL8 Cells;背景說明：彌漫大B淋巴瘤；腹腔積液轉(zhuǎn)移；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：OCI Ly19細(xì)胞、N1E115細(xì)胞、GM05887細(xì)胞

GM20956 Cells(提供STR鑒定圖譜)

HAP1 KLHDC3 (-) 3 Cells(提供STR鑒定圖譜)

Centre Antoine Lacassagne-39 Cells;背景說明：外陰鱗癌細(xì)胞；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Mv 1 Lu (NBL-7)細(xì)胞、High 5細(xì)胞、CD 18細(xì)胞

NCIH2066 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每周換液２-３次;生長特性：懸浮生長;形態(tài)特性：聚團(tuán)懸浮;相關(guān)產(chǎn)品有：CAL-62細(xì)胞、hTERT-HME-1細(xì)胞、SUDHL10細(xì)胞

COLO 320 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：THLE-2細(xì)胞、UM-UC-3細(xì)胞、NCI-H1876細(xì)胞

HuH6 Cells;背景說明：肝癌。據(jù)說產(chǎn)球蛋白和甲胎蛋白。;傳代方法：消化３-５分鐘。１：２。６-７天長滿。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Mel526細(xì)胞、LC1細(xì)胞、Wistar Institute, Susan Hayflick細(xì)胞

KYSE 30 Cells;背景說明：來源于一位６４歲，患有高分化的中段食管鱗癌的男性患者。;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：P3HR1細(xì)胞、EA.Hy926細(xì)胞、PCI-04B細(xì)胞

RPMI 6666 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：TOV-112細(xì)胞、Fetal Human Colon細(xì)胞、NCI-H1437細(xì)胞

HTh 74 Cells;背景說明：未分化甲狀腺癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MDA-MB-415細(xì)胞、GM00637細(xì)胞、IOSE-Mar細(xì)胞

NOMO1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代；;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Keio University-19-19細(xì)胞、Evsa T細(xì)胞、Kit 225 K6細(xì)胞

HPS3394 Cells(提供STR鑒定圖譜)

K-23-L Cells(提供STR鑒定圖譜)

MDTC-HP117 Cells(提供STR鑒定圖譜)

NG-3Y1-D303 Cells(提供STR鑒定圖譜)

PW Cells(提供STR鑒定圖譜)

Ubigene HEK293 CBLB KO Cells(提供STR鑒定圖譜)

WEHI-164R Cells(提供STR鑒定圖譜)

HCT116-SLC12A8-KO-c5 Cells(提供STR鑒定圖譜)

NCI-H841 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３—１：５傳代，;生長特性：混合型生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：BNL.1ME A.7R.1細(xì)胞、NOZAWA細(xì)胞、Colo16細(xì)胞

AR-42J Cells;背景說明：在腎上腺皮質(zhì)激素刺激下可誘導(dǎo)出外分泌活性，并伴有廣泛的內(nèi)質(zhì)網(wǎng)重構(gòu)。;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長滿。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：SCC4細(xì)胞、RAEC細(xì)胞、RCC_7860細(xì)胞

BC-020 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：C-8161細(xì)胞、Vero E6細(xì)胞、B-16細(xì)胞

MDAPC2B Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代，２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：M07e細(xì)胞、H2106細(xì)胞、SF539細(xì)胞

HEK/EBNA Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：１０傳代；每周２次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：K 562細(xì)胞、HT3細(xì)胞、NCI-H1693細(xì)胞

HEK/EBNA Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：１０傳代；每周２次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：K 562細(xì)胞、HT3細(xì)胞、NCI-H1693細(xì)胞

Panc 8.13 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：BC-3H-1細(xì)胞、TOV-112D細(xì)胞、Medical Research Council cell strain-5細(xì)胞

CORL105 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HT-29細(xì)胞、Ontario Cancer Institute-Acute Myeloid Leukemia-3細(xì)胞、MDA-MB 361細(xì)胞

MDA-MB-330 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：U-226AR1細(xì)胞、SNU-216細(xì)胞、HLE B-3細(xì)胞

MKN28 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：TOV112細(xì)胞、D324細(xì)胞、SKLU1細(xì)胞

HECCL-1 Cells;背景說明：子宮內(nèi)膜癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：K422細(xì)胞、OK細(xì)胞、H-1694細(xì)胞

HEK/EBNA Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：１０傳代；每周２次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：K 562細(xì)胞、HT3細(xì)胞、NCI-H1693細(xì)胞

NCI-H508 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：293-H細(xì)胞、NCI660細(xì)胞、JVM3細(xì)胞

MCF.7 Cells;背景說明：MCF-７細(xì)胞保留了多個分化了的乳腺上皮的特性，包括：能通過胞質(zhì)雌激素受體加工雌二醇并能形成圓形復(fù)合物（domes）。該細(xì)胞含有Tx-４癌基因。腫瘤壞死因子α（TNFalpha）可以抑制MCF-７細(xì)胞的生長?？勾萍に靥幚砑?xì)胞能調(diào)變IGFBP＇S的分泌。;傳代方法：１：２傳代，３-４天長滿;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：SKNEP1細(xì)胞、HCEC細(xì)胞、AGS細(xì)胞

MC/9 Cells;背景說明：肥大細(xì)胞；C５７BL/６ x A/J;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：A7r5細(xì)胞、H-1355細(xì)胞、CMEC/D3細(xì)胞

SORMi002-A Cells(提供STR鑒定圖譜)

HCC-95 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Kit-225細(xì)胞、HDQ-P1細(xì)胞、DMS-273細(xì)胞

624mel Cells;背景說明：黑色素瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：COLO206細(xì)胞、K-562細(xì)胞、HUT-28細(xì)胞

IEC18 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：MB231細(xì)胞、SU-DHL1細(xì)胞、QBC-939細(xì)胞

HCEC-12 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：GM-637細(xì)胞、HSF2細(xì)胞、Normal Rat Kidney-49F細(xì)胞

HOS (TE85, Clone F5) Cells;背景說明：骨肉瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：JurkatE6-1細(xì)胞、HGE細(xì)胞、OCI-Ly03細(xì)胞

DHL8 Cells;背景說明：彌漫大B淋巴瘤；腹腔積液轉(zhuǎn)移；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Rat Chondrosarcoma Swarm細(xì)胞、Hu-P-T4細(xì)胞、SBC5細(xì)胞

MKN-45人胃癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

Simpson Cells;背景說明：來源于一位６１歲的男性漿細(xì)胞瘤患者；可產(chǎn)生免疫球蛋白輕鏈，未檢測到重鏈。;傳代方法：按１：２傳代，５-６小時可以看到細(xì)胞分裂;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：RERFLCMS細(xì)胞、TE-9細(xì)胞、UMRC-2細(xì)胞

COLO-205 Cells;背景說明：該細(xì)胞系是１９５７年由T.U.Sample等從患有結(jié)腸癌的７０歲男性白人的腹水中分離的。該病人在取腹水樣品前已用５-尿嘧啶治療４~６周。角蛋白免疫過氧化物酶染色陽性；產(chǎn)生CEA、IL１０。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：NCI-H1105細(xì)胞、COV 434細(xì)胞、NMCG-1細(xì)胞

Jurkat E6.1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H-1869細(xì)胞、H2291細(xì)胞、NCI522細(xì)胞

C17.2 Cells;背景說明：神經(jīng)干細(xì)胞；C５７BL/６ x CD-１;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：U 138 MG細(xì)胞、NIE-115細(xì)胞、UMC11細(xì)胞

OCI-LY-19 Cells;背景說明：彌漫大B淋巴瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CCD-18Co細(xì)胞、EC9706細(xì)胞、CX1細(xì)胞

VP 267 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Statens Seruminstitut Rabbit Cornea細(xì)胞、PG13細(xì)胞、OV1-P細(xì)胞

Epithelioma Papulosum Cyprini Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SNB19細(xì)胞、RASMC細(xì)胞、Det. 562細(xì)胞

GM07404 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NE-4C細(xì)胞、HeLaS3細(xì)胞、NCI-H522細(xì)胞

BayGenomics ES cell line CSH052 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line RRU421 Cells(提供STR鑒定圖譜)

BBLC107.5 Cells(提供STR鑒定圖譜)

Keck MirKO ES cell line Mirc28 Cells(提供STR鑒定圖譜)

PCRP-ZNF326-3E7 Cells(提供STR鑒定圖譜)

ND7 Cells(提供STR鑒定圖譜)

" "PubMed=6862145; DOI=10.20772/cancersci1959.74.2_240

Naito S., Inoue S., Kinjo M., Tanaka K.

Thromboplastic and fibrinolytic activities of cultured human gastric cancer cell lines.

Gann 74:240-247(1983)

PubMed=3986962; DOI=10.1093/carcin/6.4.549

Watatani M., Ikenaga M., Hatanaka T., Kinuta M., Takai S.-i., Mori T., Kondo S.

Analysis of N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced DNA damage in tumor cell strains from Japanese patients and demonstration of MNNG hypersensitivity of Mer xenografts in athymic nude mice.

Carcinogenesis 6:549-553(1985)

PubMed=3962675; DOI=10.1111/j.1440-1827.1986.tb01461.x

Motoyama T., Hojo H., Watanabe H.

Comparison of seven cell lines derived from human gastric carcinomas.

Acta Pathol. Jpn. 36:65-83(1986)

PubMed=2105279; DOI=10.1002/ijc.2910450117

Watson S.A., Durrant L.G., Morris D.L.

The effect of the E2 prostaglandin enprostil, and the somatostatin analogue SMS 201 995, on the growth of a human gastric cell line, MKN45G.

Int. J. Cancer 45:90-94(1990)

PubMed=1778766; DOI=10.1111/j.1349-7006.1991.tb01816.x; PMCID=PMC5918361

Takeshima E., Hamaguchi M., Watanabe T., Akiyama S., Kataoka M., Ohnishi Y., Xiao H.-Y., Nagai Y., Takagi H.

Aberrant elevation of tyrosine-specific phosphorylation in human gastric cancer cells.

Jpn. J. Cancer Res. 82:1428-1435(1991)

PubMed=1846553; DOI=10.1038/bjc.1991.14; PMCID=PMC1971664

Durrant L.G., Watson S.A., Hall A., Morris D.L.

Co-stimulation of gastrointestinal tumour cell growth by gastrin, transforming growth factor alpha and insulin like growth factor-I.

Br. J. Cancer 63:67-70(1991)

PubMed=1933850

Yamada Y., Yoshida T., Hayashi K., Sekiya T., Yokota J., Hirohashi S., Nakatani K., Nakano H., Sugimura T., Terada M.

p53 gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases.

Cancer Res. 51:5800-5805(1991)

PubMed=2061947; DOI=10.1093/jnci/83.12.866

Watson S.A., Durrant L.G., Wencyk P.M., Watson A.L., Morris D.L.

Intracellular gastrin in human gastrointestinal tumor cells.

J. Natl. Cancer Inst. 83:866-871(1991)

PubMed=1370612; DOI=10.1016/S0006-291X(05)80133-0

Matozaki T., Sakamoto C., Matsuda K., Suzuki T., Konda Y., Nakano O., Wada K., Uchida T., Nishisaki H., Nagao M., Kasuga M.

Missense mutations and a deletion of the p53 gene in human gastric cancer.

Biochem. Biophys. Res. Commun. 182:215-223(1992)

PubMed=1486568; DOI=10.1016/0165-4608(92)90350-H

Rege-Cambrin G., Scaravaglio P., Carozzi F., Giordano S., Ponzetto C., Comoglio P.M., Saglio G.

Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene.

Cancer Genet. Cytogenet. 64:170-173(1992)

DOI=10.1016/B978-0-12-333530-2.50014-9

Sekiguchi M., Suzuki T.

Gastric tumor cell lines.

(In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.287-316; Academic Press; New York; USA (1994)

PubMed=9023415; DOI=10.1006/cimm.1996.1062

Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.

HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.

Cell. Immunol. 175:101-110(1997)

PubMed=9247707; DOI=10.1080/15216549700202901

Hatakeyama S., Gao Y.-H., Ohara-Nemoto Y., Kataoka H., Satoh M.

Expression of bone morphogenetic proteins of human neoplastic epithelial cells.

Biochem. Mol. Biol. Int. 42:497-505(1997)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D

Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.

Screening the p53 status of human cell lines using a yeast functional assay.

Mol. Carcinog. 19:243-253(1997)

PubMed=9665481; DOI=10.1016/S0002-9440(10)65561-7; PMCID=PMC1852940

Paciucci R., Vila M.R., Adell T., Diaz V.M., Tora M., Nakamura T., Real F.X.

Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met.

Am. J. Pathol. 153:201-212(1998)

PubMed=11107048; DOI=10.1046/j.1440-1827.2000.01117.x

Yokozaki H.

Molecular characteristics of eight gastric cancer cell lines established in Japan.

Pathol. Int. 50:767-777(2000)

PubMed=11314020; DOI=10.1038/sj.onc.1204160

Kataoka H., Miura Y., Joh T., Seno K., Tada T., Tamaoki T., Nakabayashi H., Kawaguchi M., Asai K., Kato T., Itoh M.

Alpha-fetoprotein producing gastric cancer lacks transcription factor ATBF1.

Oncogene 20:869-873(2001)

PubMed=11668190; DOI=10.1177/002215540104901105

Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.

Immunocytochemical analysis of cell lines derived from solid tumors.

J. Histochem. Cytochem. 49:1369-1378(2001)

PubMed=15723654; DOI=10.1111/j.1349-7006.2005.00016.x; PMCID=PMC11160020

Takada H., Imoto I., Tsuda H., Sonoda I., Ichikura T., Mochizuki H., Okanoue T., Inazawa J.

Screening of DNA copy-number aberrations in gastric cancer cell lines by array-based comparative genomic hybridization.

Cancer Sci. 96:100-110(2005)

PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234

Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., Yamori T.

Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.

Mol. Cancer Ther. 4:399-412(2005)

PubMed=15900046; DOI=10.1093/jnci/dji133

Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y., Yamazaki K., Hamada J.-i., Tada M., Moriuchi T., Ishikawa Y., Kato Y., Tomoda H., Yamori T., Tsuruo T.

p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target.

J. Natl. Cancer Inst. 97:765-777(2005)

PubMed=15901131; DOI=10.1016/j.prp.2005.01.002

Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.

Correlation between DNA alterations and p53 and p16 protein expression in cancer cell lines.

Pathol. Res. Pract. 201:109-115(2005)

PubMed=18804159; DOI=10.1016/j.ygeno.2008.08.002

Jung J.-J., Jeung H.-C., Chung H.C., Lee J.O., Kim T.S., Kim Y.T., Noh S.H., Rha S.Y.

In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer.

Genomics 93:52-61(2009)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

PubMed=22531121; DOI=10.2739/kurumemedj.58.73

Koga A., Aoyagi K., Imaizumi T., Miyagi M., Shirouzu K.

Comparison between the gastric cancer cell line MKN-45 and the high-potential peritoneal dissemination gastric cancer cell line MKN-45P.

Kurume Med. J. 58:73-79(2011)

PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017

Kong D.-X., Yamori T.

JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.

Bioorg. Med. Chem. 20:1947-1951(2012)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

PubMed=23671654; DOI=10.1371/journal.pone.0063056; PMCID=PMC3646030

Lu Y.-H., Soong T.D., Elemento O.

A novel approach for characterizing microsatellite instability in cancer cells.

PLoS ONE 8:E63056-E63056(2013)

PubMed=24587255; DOI=10.1371/journal.pone.0090155; PMCID=PMC3937424

Endo F., Nishizuka S.S., Kume K., Ishida K., Katagiri H., Ishida K., Sato K., Iwaya T., Koeda K., Wakabayashi G.

A compensatory role of NF-kappaB to p53 in response to 5-FU-based chemotherapy for gastric cancer cell lines.

PLoS ONE 9:E90155-E90155(2014)

PubMed=24807215; DOI=10.1038/ncomms4830; PMCID=PMC4024760

Liu J.-F., McCleland M.L., Stawiski E.W., Gnad F., Mayba O., Haverty P.M., Durinck S., Chen Y.-J., Klijn C., Jhunjhunwala S., Lawrence M., Liu H.-B., Wan Y.-N., Chopra V.S., Yaylaoglu M.B., Yuan W.-L., Ha C., Gilbert H.N., Reeder J., Pau G., Stinson J., Stern H.M., Manning G., Wu T.D., Neve R.M., de Sauvage F.J., Modrusan Z., Seshagiri S., Firestein R., Zhang Z.-M.

Integrated exome and transcriptome sequencing reveals ZAK isoform usage in gastric cancer.

Nat. Commun. 5:3830.1-3830.8(2014)

PubMed=25343454; DOI=10.1371/journal.pone.0111146; PMCID=PMC4208810

Choong M.-L., Tan S.-H., Tan T.-Z., Manesh S., Ngo A., Yong J.W.-Y., Yang H.H., Lee M.A.

Molecular integrative clustering of Asian gastric cell lines revealed two distinct chemosensitivity clusters.

PLoS ONE 9:E111146-E111146(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miroo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076

Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=29435981; DOI=10.1002/ijc.31304

Kim H.J., Kang S.K., Kwon W.S., Kim T.S., Jeong I., Jeung H.-C., Kragh M., Horak I.D., Chung H.C., Rha S.Y.

Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor.

Int. J. Cancer 143:151-159(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)"